Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

3.33
+0.01000.30%
Post-market: 3.30-0.0300-0.90%19:58 EST
Volume:2.22M
Turnover:7.40M
Market Cap:770.75M
PE:-4.84
High:3.40
Open:3.35
Low:3.25
Close:3.32
52wk High:3.60
52wk Low:0.7100
Shares:231.46M
Float Shares:183.82M
Volume Ratio:0.73
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6874
EPS(LYR):-0.2499
ROE:-783.37%
ROA:-34.25%
PB:-9.36
PE(LYR):-13.33

Loading ...

Cantor says has reinforced conviction on Gossamer Bio ahead of data readout

TIPRANKS
·
Sep 11

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Sep 11

Gossamer Bio Inc. Announces Stock Option Inducement Plan for New Employees

Reuters
·
Sep 11

Gossamer Bio Shares Rise After UBS Upgrade, PT Increase

MT Newswires Live
·
Sep 11

Gossamer Bio Inc : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
Sep 10

Gossamer Bio Raised to Buy From Neutral by UBS

Dow Jones
·
Sep 10

Gossamer Bio Inc. Unveils Presentation Highlighting Innovative Therapies for Pulmonary Hypertension and Progress on Seralutinib Trials

Reuters
·
Sep 03

Gossamer Bio Inc. to Present at Cantor Global Healthcare Conference in New York

Reuters
·
Aug 29

Director Sandra Milligan Reports Acquisition of Gossamer Bio Inc. Common Shares

Reuters
·
Aug 21

Gossamer Bio Inc. Announces New Stock Option Grants for Employees Under 2023 Inducement Plan

Reuters
·
Aug 08

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Aug 08

Gossamer Bio Is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 07

BRIEF-Gossamer Bio Q2 EPS USD -0.17

Reuters
·
Aug 06

Gossamer Bio Reports Q2 2025 Net Loss of $38.3M vs. $49.2M Net Income in 2024; Revenue Drops to $11.5M from $95.8M Due to Prior Year One-Time License Sale

Reuters
·
Aug 06

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 06

Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target

MT Newswires Live
·
Jul 14

Gossamer Bio Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 26

Gossamer Bio Completes Enrollment in Phase 3 PROSERA Study for PAH Treatment, Topline Results Expected February 2026

Reuters
·
Jun 16

Gossamer Bio Inc. Enters Global Collaboration Agreement with Chiesi Group for Development of Seralutinib

Reuters
·
Jun 16

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Jun 07